The Energy Code

Dr. Mike Belkowski
  • 5,0 (1)
  • MEDICINA ALTERNATIVA
  • OGNI SETTIMANA

The Energy Code is your blueprint for unlocking limitless vitality at the cellular level. Hosted by Dr. Mike Belkowski, this podcast dives deep into the science of your mitochondria—the true engines of health and energy. From light, water, and magnetism to groundbreaking molecules and lifestyle upgrades, each episode decodes the most effective strategies to strengthen your “Mitochondrial Matrix.” If you’re seeking cutting-edge science, practical tools, and proven methods to optimize your body and mind, you’ve just cracked the code. Check out these sources: www.biolight.shop – Instagram @biolight.shop – YouTube BioLight

  1. 30 MIN FA

    Does Red Light to the Brain Boost Endurance In Trained Cyclists? What the Data Actually Says

    Transcranial photobiomodulation (tPBM) is everywhere in performance culture —shine near-infrared light on the prefrontal cortex and supposedly you get better oxygenation, lower perceived effort, delayed central fatigue, and improved endurance. This Deep Dive episode breaks down a clean, double-blind crossover study in trained cyclists who rode their own bikes through a standardized constant-load effort followed by a 25-minute time trial. The conclusion was clear: acute tPBM at 810nm (40Hz, 20 minutes, with an intranasal component) did not improve performance, heart rate, lactate, perceived exertion, or pacing dynamics versus sham. The real value is what the null result teaches: dose, penetration, target engagement, and context matter —especially in trained athletes. (Educational content only, not medical advice.) - Article Discussed in Episode: Effects of transcranial photobiomodulation on performance and cardiovascular responses in trained cyclists - Key Quotes From Dr. Mike: “Does it (tPBM) actually work in real athletes under real performance conditions with real outcomes like power, heart rate, and pacing?” “Can enough light penetrate scalp and skull to meaningfully modulate cortical function?” “Parameters matter, penetration matters, and athletes are a hard population to move.” “Wavelength and irradiance aren’t specs for marketing — they’re the difference between signal and nothing.” - Key Points Clean test of hype: trained cyclists, double-blind, randomized crossover, real performance outcomes. Protocol: 20 min tPBM (810nm, 40Hz; prefrontal targeting + intranasal probe), then warm-up → 15-min constant load → 25-min time trial. Result: no meaningful differences vs sham in power, HR, lactate, RPE, or efficiency-style ratios. Likely explanations: insufficient cortical photon dose/penetration, parameter selection (wavelength/irradiance), acute vs chronic effects, no direct confirmation of brain “target engagement,” athlete ceiling effects. Takeaway: null results are useful—optimize parameters, verify engagement (fNIRS/EEG), test chronic protocols, and match outcomes to what the PFC actually influences (pacing decisions, inhibition, interoception). - Episode timeline 0:19–1:42 — The promise vs the test: trained cyclists + double-blind crossover; headline null result 1:59–3:27 — Why tPBM could work: mitochondria, CCO, ATP/NO/redox; PFC role in pacing & effort 3:28–4:55 — The real question: can enough light reach cortex in trained athletes? Study design + protocol 5:13–5:59 — What they measured: HR, lactate, RPE, time-trial power, power/HR and power/RPE trends 6:10–7:35 — Results: expected fatigue drift in both blocks, no separation between PBM and sham 7:44–10:52 — Why it may have failed: penetration, dosimetry, wavelength, acute vs chronic, ceiling effect 10:57–11:59 — What good science does: treat null as signal; what to optimize next 12:05–13:56 — BioLite lens: tissue accessibility vs skull barrier; “systems not magic”; stack fundamentals 14:02–15:17 — Closing: what the study proves (and what it doesn’t); next episode tease - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

    16 min

  2. 1 G FA

    Can Red Light Actually Lower Blood Sugar? Early Clinical Trials Suggest a Real Signal (Not a Miracle)

    Can photobiomodulation (red + near-infrared light) meaningfully improve glycemic control in people with type 2 diabetes? In this Deep Dive, Dr. Mike Belkowski breaks down a 2026 systematic review of randomized clinical trials that tested PBM for diabetes outcomes like fasting glucose, post-prandial glucose, and HbA1c. The evidence base is small — only 4 RCTs met strict inclusion criteria (control/sham required) — but the signal was generally favorable: PBM was associated with reductions in fasting glucose, post-prandial glucose, and HbA1c, and in some studies improvements in lipid markers. The catch is that overall certainty is very low to low due to small samples, protocol heterogeneity, and bias concerns. Translation: promising adjunct, not proven therapy, and not remotely a replacement for standard care. (Educational content only, not medical advice.) - Article Discussed in Episode: Photobiomodulation Therapy to Improve Glycemic Control in People with Diabetes Mellitus: A Systematic Review - Key Quotes From Dr. Mike: “Type 2 diabetes… chronic hyperglycemia disrupts mitochondrial metabolism, increases oxidative stress, activates inflammatory pathways…” “PBM, mostly red and near infrared wavelengths, was associated with reductions in fasting glucose, postprandial glucose, and HBA1C.” “These were longer protocols, 30 minutes per session, 3 sessions per week for 12 weeks.” “PBM is not a replacement for medication, nutrition, exercise, or medical monitoring.” “We’re early, but the direction is real.” - Key Points The review included 4 randomized clinical trials (1993–2025 search; control/sham required). Outcomes emphasized fasting glucose, post-prandial glucose, HbA1c, plus some cardiometabolic measures. Overall finding: PBM was generally associated with improved glycemic markers, sometimes lipids too. Evidence certainty: very low to low (small N, heterogeneity, some risk-of-bias concerns). Protocol types: Wrist “watch” PBM over radial pulse area: 30 min, 3x/week, 12 weeks, often alongside meds. LED pad PBM over large tissue regions (limbs/abdomen): crossover, sham-controlled, acute/time-response.   Dose response looks biphasic (a “sweet spot”): one trial found 100 J sustained lower glycemia up to 12 hours, while higher dose wasn’t clearly better. Mechanistic framework: mitochondria/CCO, NO & microcirculation, ROS → Ca²⁺ → AMPK, and GLUT4 translocation. Bottom line: PBM is a plausible metabolic signal and an early clinical adjunct candidate—but the field needs larger, standardized RCTs and clearer dose-response mapping. - Episode timeline 0:19–1:26 — The “futuristic” question + disclaimer (PBM as adjunct, not replacement) 1:30–3:20 — Why PBM could matter in T2D (hyperglycemia → mito dysfunction/oxidative stress loop) 3:24–4:51 — Systematic review methods + headline result (only 4 RCTs; generally favorable; low certainty) 5:04–6:03 — Trial type #1: wrist “watch” PBM over radial pulse (12-week adjunct outcomes) 6:03–7:28 — Trial type #2: LED pad PBM over larger tissue areas (crossover; acute/time-response; dose effects) 7:28–8:40 — Biphasic response explanation + quality/bias ratings (PEDro, ROB2, GRADE) 8:41–10:34 — Mechanisms: bioenergetics, NO/microcirculation, ROS→AMPK, GLUT4 10:34–11:58 — Nuance: mixed literature; protocol variability likely drives inconsistent results 12:02–13:26 — The Energy Code conclusion: promising adjunct, early evidence, needs standardization - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

    14 min

  3. 1 G FA

    Alzheimer’s Isn’t “Just Aging”: Human Brain Data Shows a Distinct Mitochondrial Collapse — Especially in the Hippocampus

    Most conversations about Alzheimer’s and mitochondria stay in broad strokes. This Deep Dive episode doesn’t. Dr. Mike Belkowski breaks down a study that examined postmortem human brain tissue to answer a precise question: do mitochondrial electron transport chain proteins shift in Alzheimer’s the same way they shift in normal aging — or is Alzheimer’s a different mitochondrial pattern entirely? Using three groups (young controls 35–45, aged controls >85 without Alzheimer’s pathology, and sporadic Alzheimer’s cases 85–89), the researchers measured neuron-level immunohistochemical intensity (a proxy for relative protein abundance) for key mitochondrial markers: complex IV subunits MTCO1/MTCO2, complex V (ATP synthase), and IF1, the ATP synthase inhibitory factor that helps prevent catastrophic ATP “backwards burning” during stress and supports crista integrity. The core finding: Alzheimer’s shows electron transport chain instability that differs from physiological aging, and the hippocampus (CA1/CA2) stands out as a failure zone — losing IF1 and failing to mount the compensatory ATP synthase response seen in other regions. In Energy Code terms: memory circuits are energy-expensive, and Alzheimer’s appears to remove mitochondrial protection exactly where it’s needed most. (Educational content only, not medical advice.) - Article Discussed in Episode: Immunohistochemical Markers of Mitochondrial Electron Transport Chain Instability in Human Brain Regions: A Study of Aging and Alzheimer’s Disease - Key Quotes From Dr. Mike: “Do the mitochondrial electron transport chain proteins change in Alzheimer’s… or is Alzheimer’s a fundamentally different mitochondrial pattern?” “Alzheimer’s shows a pattern of mitochondrial electron transport chain instability that is fundamentally distinct from physiological aging.” “The hippocampus appears to be uniquely vulnerable because it fails to mount a protective compensatory response.” “Alzheimer’s shows instability, and the hippocampus stands out as a failure zone.” “Memory circuits depend on mitochondrial resilience… and the hippocampus loses mitochondrial protection exactly where it needs it most.” - Key Points The study compares young controls, aged controls, and sporadic Alzheimer’s using human brain tissue. Multiple regions were analyzed: middle frontal gyrus, anterior cingulate, caudate, hippocampus CA1/CA2, inferior parietal lobule. Markers measured (IHC intensity proxy): MTCO1 + MTCO2 (complex IV), complex V (ATP synthase marker), IF1. Complex IV subunit imbalance (MTCO1 ↓ while MTCO2 ↑) is repeatedly seen in Alzheimer’s → suggests complex IV stoichiometry/assembly instability and potential ↑electron leak/ROS. IF1 matters because it: inhibits reverse ATP hydrolysis by ATP synthase during stress (energy-preserving) supports crista architecture via ATP synthase dimer stabilization   Many cortical regions show Alzheimer’s-associated compensatory increases in complex V and IF1. Hippocampus is the exception: IF1 drops and complex V fails to rise → reduced protection against energy collapse. Conclusion: Aging ≠ early Alzheimer’s; Alzheimer’s shows a distinct mitochondrial signature, with hippocampal vulnerability linked to failure of adaptive response. Limitations: IHC is indirect (protein pattern proxy, not respiration measurements), but the region-specific patterns are coherent. - Episode timeline 0:19–1:24 — The core question + headline conclusion (Alzheimer’s vs aging mitochondrial pattern) 1:26–2:33 — Study design: groups, ages, regions analyzed 2:33–3:12 — What they measured: MTCO1, MTCO2, complex V, IF1 (IHC intensity proxy) 3:19–5:32 — Why these proteins matter: complex IV roles; ATP synthase; IF1 as protector + crista stabilizer 5:34–7:58 — Region-by-region patterns (frontal cortex, anterior cingulate, caudate): instability vs compensation 8:02–9:48 — Hippocampus CA1/CA2: the “failure zone” (IF1 down + no complex V compensation) 9:57–11:54 — Energy Code synthesis: aging ≠ Alzheimer’s; complex IV instability + hippocampal loss of protection 12:01–12:23 — Limitations (IHC proxy vs functional measures) 12:26–14:18 — Implications: early mitochondrial stability/quality-control strategy; why memory is hit first - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

    15 min

  4. 2 GG FA

    Mitophagy: The Invisible Process That Quietly Controls Aging, Inflammation, Brain Resilience (and Disease Risk)

    Mitophagy is the body’s targeted mitochondrial cleanup system; not general autophagy, but the precise identification and removal of damaged mitochondria so cells can recycle parts and rebuild stronger. In this Deep Dive, Dr. Mike Belkowski breaks down a newly published review, “Mitophagy in the Pathogenesis and Management of Disease,” and explains why mitophagy is more than housekeeping — it’s a strategic control system for mitochondrial integrity, metabolic balance, redox signaling, and immune tone. You’ll learn the two major mitophagy “toolkits” (ubiquitin-mediated PINK1/Parkin and receptor-mediated pathways like BNIP3/NIX/FUNDC1), why basal mitophagy doesn’t always depend on PINK1/Parkin, how lipids like cardiolipin can act as mitophagy signals, and why “piecemeal mitophagy” may preserve mitochondria without scrapping the whole organelle. Then the episode maps how mitophagy dysregulation shows up across neurodegeneration, immune dysfunction, metabolic disease, cardiovascular disease, and cancer — where mitophagy can be both tumor-suppressive and tumor-supportive depending on context. Finally, it closes with the therapeutic frontier: precision mitophagy medicine (i.e., right pathway, right tissue, right timing, right intensity). (Educational content only, not medical advice.) - Article Discussed in Episode: Mitophagy in the pathogenesis and management of disease - Key Quotes From Dr. Mike: “Mitophagy is the targeted removal of damaged mitochondria.” “When mitophagy works, you maintain mitochondrial quality.” “When mitophagy fails or becomes dysregulated… oxidative stress rises, inflammation gets louder.” “The goal is not maximum mitophagy, the goal is appropriate mitophagy.” “Urolithin A is the only clinically validated bioactive compound shown to enhance mitophagy in humans so far.” - Key Points Mitophagy = targeted removal of damaged mitochondria (not general autophagy). It’s a control system for mitochondrial integrity, redox balance, immune tone, and metabolic resilience. Mitochondria require coordination between mtDNA + nuclear DNA; mitonuclear imbalance drives proteotoxic stress. Quality control layers: biogenesis, fusion/fission, proteostasis/UPRmt, MDVs—mitophagy is the bulk disposal pathway. Two main signaling routes: Ubiquitin-mediated: PINK1 → phosphorylated ubiquitin → Parkin → ubiquitin coat → OPTN/NDP52 → autophagosome → lysosome. Receptor-mediated: BNIP3/NIX/FUNDC1 (hypoxia-linked) + others (BCL2L13, FKBP8, AMBRA1, PHB2).   Basal mitophagy in vivo often isn’t PINK1/Parkin-dependent → mitophagy is a toolkit, not one pathway. Lipids can signal mitophagy: cardiolipin externalization, ceramide involvement in certain stress states. Piecemeal mitophagy can remove components without destroying the entire organelle. Disease relevance: impaired mitophagy → ↑ROS, ↓ATP, calcium instability, mtDNA danger signals → cGAS–STING / AIM2 / NLRP3 → IL-1β, IL-18. Therapeutics are context-dependent: boosting isn’t always better; sometimes inhibition may help (certain cancers/antiviral defense). Highlight: Urolithin A discussed as clinically validated for enhancing mitophagy in humans (proof-of-concept milestone). Future: precision mitophagy medicine—mechanism-matched interventions and better biomarkers. - Episode timeline 0:19–2:42 — Why mitophagy matters + 3-part roadmap + disclaimer 2:49–4:49 — Mitochondria as signaling hubs; mitonuclear imbalance; layers of quality control 4:51–7:20 — Mitophagy “eat-me” signals; ubiquitin vs receptor-mediated; PINK1/Parkin steps + key nuance about basal mitophagy 7:20–10:22 — Receptor pathways (BNIP3/NIX/FUNDC1 + others), inner-membrane PHB2, lipid signals (cardiolipin/ceramides) 10:27–11:04 — Piecemeal mitophagy: selective repair vs whole-organelle removal 11:04–12:21 — Why dysfunction drives disease: ROS, mtDNA danger signals, inflammasomes; mitophagy as anti-inflammatory control 12:21–13:39 — Neurodegeneration (Parkinson’s, Alzheimer’s, Huntington’s, ALS) 13:39–15:31 — Immune regulation, autoimmunity (lupus/IBD), metabolic disease nuance (too little vs too much) 15:31–16:23 — Cardiovascular disease: ischemia-reperfusion timing + heart failure 16:23–17:40 — Cancer: dual role (tumor suppression vs survival advantage under therapy stress) 17:40–20:22 — Therapeutics + precision: UA, NAD+ strategies, spermidine, exercise, rapamycin; need for selective mitophagy drugs - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

    22 min

  5. 3 GG FA

    ROS & Cancer: Why “Antioxidants Prevent Cancer” is Too Simple (and How Tumors Use Oxidation to Survive)

    Reactive oxygen species (ROS) sit at the center of modern cancer biology and the conversation around them is often wildly oversimplified. In this Deep Dive, Dr. Mike Belkowski explains why ROS are not “bad molecules,” but cellular signaling messengers that can be hijacked by tumors. The core framework is the one you need to remember: ROS has a dual role in cancer —moderate ROS can support tumor growth and therapy resistance, while excessive ROS can push cancer cells into programmed death (including ferroptosis). You’ll learn the major ROS species (signaling vs damage), where ROS comes from (mitochondria, peroxisomes, ER, NOX enzymes + environmental sources), how tumors walk a redox tightrope using NRF2 to stay below toxic thresholds, and how redox biology controls angiogenesis, metastasis, drug resistance, and immune evasion. Finally, the episode lands on the mature therapeutic vision: personalized redox oncology — profiling a tumor’s “redox signature” to decide when to inhibit ROS signaling vs when to push ROS past the cancer cell’s tolerance threshold, often in combination with standard therapy. (Educational content only, not medical advice.) - Article Discussed in Episode: Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications - Key Quotes From Dr. Mike: “ROS have a dual role in cancer." “Moderate ROS can help tumors grow and resist therapy, while excessive ROS can push cancer cells into programmed cell death.” “Mitochondria are not just energy factories, they’re redox generators and redox regulators.” “The future vision is personalized redox oncology.” “Cancer is a redox game.” - Key Points ROS are signaling molecules, not just damage molecules; cancer hijacks the signaling. Dual role: moderate ROS = pro-growth + resistance; excessive ROS = cell death. Hydrogen peroxide (H₂O₂) is a key signaling ROS; hydroxyl radicals are the damage ROS. Major endogenous sources: mitochondria (Complex I/III leak), peroxisomes, ER protein folding, NOX enzymes. Redox balance is governed by NRF2 — protective in healthy cells, often weaponized by tumors. Tumors live on a redox tightrope: high enough ROS to drive survival pathways, low enough to avoid self-destruction. Moderate ROS can amplify survival networks (MAPK/ERK, PI3K-AKT-mTOR, HIF-1α, NF-κB, JAK-STAT, TGF-β). Excess ROS can activate death programs: apoptosis, autophagy-dependent death, ferroptosis (iron + lipid peroxidation). ROS shapes the tumor ecosystem: angiogenesis, metastasis programs, drug efflux/NRF2 detox capacity, immune suppression (e.g., PD-L1). Two therapeutic directions: reduce pro-tumor ROS signaling or push ROS over the threshold—the hard part is selectivity. Future: redox signatures + precision combinations to increase kill rates and reduce resistance. - Episode timeline 0:19–1:39 — Why ROS is central to cancer; “ROS is both a fuel and a weapon” 1:50–3:23 — ROS defined + species differences (H₂O₂ signaling vs hydroxyl damage; superoxide upstream) 3:23–6:59 — ROS sources: mitochondria, peroxisomes, ER, NOX + exogenous exposures and immune “respiratory burst” 6:59–9:10 — Redox homeostasis + NRF2/KEAP1; tumors hijack NRF2 to survive the tightrope 9:10–11:24 — How moderate ROS drives cancer: DNA damage + pro-survival signaling networks 11:24–12:04 — Ferroptosis explained: lipid peroxidation as a kill-switch strategy 12:04–13:55 — Clinical layers ROS influences: angiogenesis, metastasis, drug resistance, immune suppression 13:55–16:17 — Therapeutic implications: lower ROS signaling vs pro-oxidant push; selectivity problem 16:17–17:18 — “Energy Code” interpretation: targeted redox imbalance, not moral narratives 17:18–18:20 — Audience takeaways (clinicians, biohackers, builders); one-line summary - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

    19 min

  6. 4 GG FA

    Red Light Therapy Just Went Mainstream: Why Nature’s Featured Article Means the Field Is Finally Growing Up (and Where the Real Proof Lives)

    Red and near-infrared light (photobiomodulation) is hitting a legitimacy inflection point; not because it “does everything,” but because the science has matured enough to demand standards. In this Deep Dive, Dr. Mike Belkowski breaks down why mainstream outlets like Nature are taking red light seriously now, what that signals about the lifecycle of a real therapy (research → niche clinics → overhype → “fad” → replication → standardization), and why this moment matters for biohackers, clinicians, and health tech. Then we go deeper than headlines: the core mitochondrial mechanism (cytochrome c oxidase, ATP, redox signaling, dosing sweet spots), the reality check on consumer devices that don’t deliver therapeutic dose, and why chronic pain is one of the best proving grounds. That's because chronic pain is a bioenergetic + inflammatory signaling problem and we now have randomized trial evidence showing PBM can reduce pain in specific populations (with protocol variability still limiting universal recommendations). Bottom line: the next 10 years is about parameters, independent testing, and indication-specific regimens — not just good vibes. (Educational content only, not medical advice.) - Article Discussed in Episode: The surprising science behind red-light therapy — and how it really works - Key Quotes From Dr. Mike: “When Nature runs a feature on red light therapy… this is no longer fringe.” “The Nature article is not a clinical guideline… it’s a signal of scientific legitimacy and a call for better standards.” “Humans are exposed to less red light than ever before…” “Light has always been medicine.” “Scientists testing commercial products find that some are beneficial, but many… fail to deliver a therapeutic dose.” “Photobiomodulation is not ‘more is better.’ It’s right dose, right tissue, right timing.” “Biohackers can be a decade plus ahead… not because they’re smarter, but because they’re earlier adopters.” - Key Points PBM has followed the predictable arc: early weird lab findings → niche clinical pockets → premature commercialization/hype → “fad” label → replication + footholds → push for standards. Nature coverage is a legitimacy signal, not a “proven for everything” endorsement. The maturity marker is the word “regimens”: parameters > hype. Modern life may mean less red/NIR exposure (indoor spectrum narrowing), prompting bigger questions about light as a missing input—not a “diagnosis,” but a legitimate hypothesis. Mechanism: red/NIR penetrates deeper; wavelengths overlap with cytochrome c oxidase (Complex IV) → ATP + downstream blood flow/inflammation/redox effects. PBM is biphasic: too little = no effect; too much = counterproductive. Consumer market problem: many devices under-dose or don’t match claims; marketing abuses real science. Chronic pain is a proving ground: pain is expensive; mitochondrial instability → hyperexcitability + neuroinflammation; RCTs show PBM often helps fibromyalgia and peripheral neuropathy with low adverse events, but protocols vary. Biohackers can be “ahead” because they adopt early mechanistic signals—responsibly means honesty about uncertainty + dosing + safety. Next era: standards, third-party verification, clear dosing language, and indication-specific recommendations. - Episode timeline 0:19–2:43 — Why this is a “maturity moment” for RLT; episode roadmap + disclaimer 3:00–5:17 — Nature recognition: legitimacy signal + red/NIR as potentially “missing environmental input” hypothesis 5:17–6:25 — Photomedicine history (UV/Vit D, Nobel 1903, SAD light therapy, psoriasis UV) + PBM lineage (1960s, NASA 1990s) 6:25–8:12 — Why legitimacy now: clinical footholds, consensus language, guideline inclusion; warning about hype + under-dosed devices 8:20–10:57 — Mechanism: penetration, cytochrome c oxidase, ATP/redox; dose sweet spot; field shifts from “does it work?” to “how do we dose it?” 11:02–12:23 — Biohackers ahead of the curve: why it happens + how to do it without hype 12:23–18:18 — Chronic pain as the proving ground: mitochondria → sensitization; mtROS loops; mtDAMPs/NLRP3; transport issues; trial evidence patterns (fibro/neuropathy strongest) 18:22–20:43 — What “maturing out of fad” looks like: parameters, independent testing, consensus statements, regulator approvals 20:54–21:57 — Responsible leadership: “real not magic” + why the market got ahead of standardization 22:12–22:50 — Future tech: wearables/AI dosing, spaceflight mitochondrial work, and environmental lighting redesign 22:50–26:04 — Energy Code/BioLight philosophy + 6 closing conclusions (lineage, footholds, coherent mechanism, pain evidence, biohackers + honesty, standards next) - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

    27 min

  7. 6 GG FA

    Chronic Pain Isn’t “In Your Head”—It’s an Energy Crisis: The Mitochondria–Inflammation Loop (and Where Red Light Fits)

    This episode builds a real framework for chronic pain by connecting two worlds that rarely get stitched together: (1) a mechanistic review arguing that mitochondrial dysfunction drives pain chronification, and (2) a systematic review of randomized clinical trials on photobiomodulation (PBM) — red/near-infrared light therapy — for chronic pain. Dr. Mike Belkowski explains why chronic pain is a bioenergetic + redox + immune signaling loop (ATP instability, mitochondrial ROS, calcium overload, neuroinflammation, and quality-control failure), then maps where PBM appears to help most in humans (especially fibromyalgia and peripheral neuropathies) while being honest about the biggest limitation: protocol variability. The punchline is practical and responsible: PBM isn’t a stand-alone magic fix — it’s best viewed as a mitochondria-targeted module inside a larger systems strategy. (Educational content only, not medical advice.) - Articles Discussed in Episode: Mitochondrial Dysfunction as a Driver of Chronic Pain: New Insights and Therapeutic Prospects Photobiomodulation in chronic pain: a systematic review of randomized clinical trials - Key Quotes From Dr. Mike: “Chronic pain is a bioenergetic problem…” “What makes chronic pain chronic is that the pain system changes.” “Pain transmission is expensive. Every action potential costs energy.” “PBM… may be one of the cleanest real-world tests of a mitochondria-first pain model.” “PBM should be seen as a module inside a larger system strategy, not a magic stand-alone fix.” - Key Points Chronic pain persists because the pain system changes: sensitization + amplification (“gain knob” turned up). Pain transmission is energy expensive; mitochondrial strain makes neurons hyperexcitable. The chronification loop: ATP instability → ROS amplification → calcium dysregulation/MPTP risk → mtDAMPs → NLRP3 + cytokines → glial amplification → more excitability → more mitochondrial damage. Mitochondrial quality control fails in chronic pain: mitophagy ↓, biogenesis ↓ (PGC-1α/NRF1/TFAM), dynamics skew (DRP1), transport disrupted. PBM is a strong real-world test because it’s fundamentally a mitochondria-influencing signal. RCT review (2015–2025) finds PBM often reduces pain, most consistently in fibromyalgia and peripheral neuropathies, with low adverse events. The limiting factor is heterogeneity: wavelengths, dose, frequency, devices, outcome measures, and follow-up windows vary widely. Responsible take: PBM is best viewed as a module inside a larger system strategy, not a stand-alone fix. Timing matters: pain chronification is a trajectory; earlier intervention may prevent “lock-in,” later intervention typically requires stacked strategies. - Episode timeline 0:41–1:33 — Mission: connect mechanistic model to RCT evidence; what each source is 1:48–2:56 — Unified pain-energy model + disclaimer 2:56–3:40 — Definition: pain persists because the system changes; “gain knob” up 3:45–6:07 — Mechanistic engine: energy crisis → ROS → calcium/MPTP → mtDAMPs/NLRP3 → QC failure → lock-in 6:14–6:54 — Clinical trials review summary: PBM often helps (fibromyalgia/neuropathy), but variability limits standardization 7:11–8:53 — Step 1: energy failure; “unstable bioenergetics” 8:53–10:18 — Step 2: mitochondrial ROS as a signaling amplifier 10:18–12:12 — Step 3: calcium overload + permeability transition 12:12–14:07 — Step 4: mtDAMPs → neuroinflammation → central sensitization loop 14:11–16:36 — Step 5: quality control failure + cell-type specificity (neurons, glia, Schwann cells) 16:36–19:06 — Pain types where mitochondrial signatures show up; therapy implications (mitoQ/mitoTEMPO, melatonin, NAD+ precursors, SS-31, etc.) 19:12–21:54 — PBM mechanisms + what RCTs found + heterogeneity 21:54–26:15 — Compare/contrast: where sources agree, where they differ, why they complement 26:22–27:18 — Integrated conclusion: mito-first model predicts PBM works best in sensitization/metabolic stress phenotypes 27:31–30:40 — Practice implications in layers (remove stressors → restore QC → PBM module → precision targeting) 30:40–31:08 — “Not in your head” clarification: it’s physiology 31:16–33:42 — Responsible PBM conclusion: promising, safe profile, needs standardization/long follow-up 34:16–34:57 — Time matters: acute → chronic trajectory 34:59–37:38 — BioLight framing + 3 conclusions (engine > symptom suppression; PBM isn’t woo; future = precision) - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

    39 min

  8. 25 MAR

    Pancreatic Cancer’s Hidden Achilles’ Heel: Targeting Mitochondria to Force Tumor Cell Death

    Pancreatic cancer is aggressive, often detected late, and notoriously resistant to standard chemotherapy. In this Deep Dive, Dr. Mike Belkowski breaks down a major frontier in oncology research: targeted mitochondrial therapy. You’ll learn why mitochondria sit at the center of tumor survival (energy production, redox control, metabolic flexibility, calcium signaling, and, most importantly, apoptosis), and how researchers are designing therapies that attack cancer’s mitochondrial vulnerabilities while trying to spare healthy tissue. The episode also explains the biggest bottleneck in the whole field— delivery into mitochondria — and why next-gen carriers (peptides, mitochondria-targeting moieties, nanoparticles, and aptamers) may determine what actually works in humans. (Educational content only, not medical advice.) - Article Discussed in Episode: Targeted mitochondrial therapy for pancreatic cancer - Key Quotes From Dr. Mike: “Pancreatic cancer… sits right at the intersection… aging, inflammation, and mitochondrial quality control.” “Pancreatic cancer cells often survive by… reprogramming metabolism and resisting apoptosis.” “Cancer cells typically run with higher baseline ROS… they live closer to the edge.” “Can we target mitochondria in a way that selectively harms cancer cells while sparing healthy tissue?” “Mitochondria… sit at the center of energy production, redox control, metabolic flexibility… and apoptosis.” - Key Points Pancreatic cancer’s core advantages: metabolic rewiring + apoptosis resistance. Cancer metabolism isn’t “Warburg only”— it’s metabolic flexibility (glycolysis vs. OXPHOS shifts within the same tumor). KRAS mutations are central drivers and also influence mitochondrial behavior and ROS signaling. Therapeutic strategy: push mitochondria from “pro-growth stress” into energy collapse and death signaling. Major mitochondrial targets include mtDNA, biogenesis, fusion/fission dynamics, redox/NADPH supply, ROS thresholds, and mitochondria-dependent apoptosis. The biggest practical constraint is mitochondrial delivery (two membranes; inner membrane selectivity). Delivery strategies highlighted: cell-penetrating peptides, mitochondria-targeting moieties (voltage-driven), nanoparticles/liposomes, and aptamer-guided systems. Main challenges: drug resistance, tumor heterogeneity, metabolic plasticity, and off-target toxicity to healthy mitochondria. Likely future: combination strategies + tumor profiling/stratification + precision delivery engineering. - Episode timeline 1:11–2:23 — Why pancreatic cancer is so hard: late detection, resistance, limited curative window 2:23–3:27 — Cancer = energy + building blocks + redox survival; Warburg nuance + metabolic flexibility 3:27–4:27 — KRAS influence; mitochondria as double-edged sword (mild vs severe dysfunction) 4:30–6:18 — Core mitochondrial targets: mtDNA, biogenesis, fusion/fission dynamics 6:18–8:24 — Metabolic regulation: glycolysis, glutamine/NADPH, OXPHOS-dependent subtypes 8:28–10:05 — ROS as vulnerability + mitochondria-dependent apoptosis (“make the cancer remember how to die”) 10:05–12:54 — The real bottleneck: mitochondrial delivery; peptides, targeting moieties, nanoparticles/liposomes, aptamers 12:54–14:50 — Hard truths: resistance, heterogeneity, toxicity risk, delivery still limiting 14:50–16:30 — Wrap: precision oncology = right payload, right cell, right organelle, right time - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

    17 min
Elenco completo (304)

Valutazioni e recensioni

Descrizione

The Energy Code is your blueprint for unlocking limitless vitality at the cellular level. Hosted by Dr. Mike Belkowski, this podcast dives deep into the science of your mitochondria—the true engines of health and energy. From light, water, and magnetism to groundbreaking molecules and lifestyle upgrades, each episode decodes the most effective strategies to strengthen your “Mitochondrial Matrix.” If you’re seeking cutting-edge science, practical tools, and proven methods to optimize your body and mind, you’ve just cracked the code. Check out these sources: www.biolight.shop – Instagram @biolight.shop – YouTube BioLight

Informazioni

  • Creatore
    Dr. Mike Belkowski
  • Anni di attività
    2021 - 2026
  • Puntate
    304
  • Classificazione
    Contenuti adatti a tutti
  • Copyright
    © Copyright 2021 All rights reserved.
  • Sito web del podcast
    The Energy Code

Potrebbero piacerti anche…